What is driving the surge in biotech megadeals?

Didier Choukroun, chief executive officer (CEO) at SPHERE Investments, believes the megadeals trend is also due to the biotech and health sectors’ resilience to economic fluctuations. “Healthcare needs remain constant regardless of economic conditions, making investments in these areas relatively stable and less risky compared to other industries. This stability is particularly attractive to investors as it offers a safeguard against market volatility.”